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Abstract
Comprehension of randomization is a vital, but understudied, component of informed consent to participate in cancer randomized clinical trials (RCTs). This study examines
patient comprehension of the randomization process as
well as sources of ongoing uncertainty that may inhibit a
patient’s ability to provide informed consent to participate
in RCTs. Cancer patients living in rural Appalachia who were
offered an opportunity to participate in a cancer treatment RCT completed in-depth interviews and a brief survey. No systematic differences in randomization comprehension between patients who consented and those who
declined participation in a cancer RCT were detected. Comprehension is conceptually distinct from uncertainty, with
patients who had both high and low comprehension experiencing randomization-related uncertainty. Uncertainty
about randomization was found to have cognitive and affective dimensions. Not all patients enrolling in RCTs have
a sufficient understanding of the randomization process
to provide informed consent. Healthcare providers need
to be aware of the different types of randomization-related uncertainty. Efforts to improve informed consent to
participate in RCTs should focus on having patients teach
back their understanding of randomization. This practice

could yield valuable information about the patient’s cognitive and affective understanding of randomization as
well as opportunities to correct misperceptions. Education
about RCTs should reflect patient expectations of individualized care by explaining how all treatments being compared are appropriate to the specifics of a patient’s disease.
Keywords: Cancer clinical trials, Oncology research, Health
disparities, Randomization, Uncertainty, Decision making

Background
Randomized clinical trials (RCTs) are the gold standard
for evaluating emerging discoveries in cancer treatments
and, as such, the approval of new cancer treatments depends on enrolling a sufficient number of participants in
a timely manner [1]. Unfortunately, advances in cancer
treatment are often delayed due to slow rates of RCT accrual, particularly among vulnerable populations such as
rural residents [2].
While enrollment in cancer RCTs is an important indicator of the extent to which vulnerable populations have
the ability to access state-of-science treatment, another
factor that should be considered is a patient’s ability to
1
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give informed consent to treatment [3]. Informed consent
in the context of RCTs is particularly challenging because
patients must understand both the nature of their disease
and associated therapies as well as the role of probability
in experimental research design in order to make an informed decision about their healthcare. Although strategies for promoting patient understanding of a cancer diagnosis, prognosis, and conventional treatment options are
well documented [4–6], more research is needed on patient
comprehension of scientific research design and randomization-related uncertainty in the context of cancer RCTs.
Randomization Comprehension
Given the importance of randomization in the informed
consent process, there is a growing body of research focused on how people understand randomization and their
attitudes about using randomization procedures to determine medical treatment in RCTs [7–10]. Kerr and colleagues showed that college students accurately identified methods of random allocation (e.g., flip of a coin), but
had negative attitudes toward using these methods to determine medical treatment [7]. Similarly, Appalachian cancer patients and their caregivers understood randomization conceptually, with different forms of gambling (e.g.,
lottery) being the most readily accessible example of random selection [8]. Unfortunately, comprehension of randomization may not be better among patients enrolled in
cancer RCTs than the general public.
Randomization-Related Uncertainty
The challenge of explaining randomization to patients lies
in the high degree of uncertainty inherent in the concept.
In most medical contexts, healthcare providers engage in
educational efforts to reduce a patient’s uncertainty about
their illness. Illness uncertainty exists when the elements of
a health situation are perceived as complicated, ambiguous, variable, or probabilistic [11–13]. In many healthcare
situations, education should decrease some forms of uncertainty [14]. However, increased knowledge about randomization cannot be expected to decrease uncertainty
because the relationship between uncertainty and probability is curvilinear [13]. Uncertainty is lowest when individuals perceive the probability of a certain event as 0 or
100 % and highest when it is 50 %. Thus, a patient with
high comprehension of randomization enrolled in a twoarm RCT should have a very high degree of uncertainty
regarding the treatment she or he will receive. The unique
relationship between comprehension and uncertainty in
the cancer RCT context is important to explore because of
the potentially significant implications for patient well-being as well as willingness to participate in medical research.
As such, the purpose of the current study is to explore the
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relationship between comprehension and uncertainty, particularly as related to cancer RCT participation among an
underserved and highest risk population.

Methods
Participants
Participants included 49 patients who were offered a cancer treatment RCT within the last 2 years and lived in or
were treated for cancer in 1 of 32 Appalachian Ohio counties. Patients were recruited from a large, urban comprehensive cancer center (n = 17, 35 %) and four rural community cancer centers (n = 32, 65 %). The sample ranged
in age from 33 to 79 years (M = 59.67, SD = 11.46) and
was predominately female (n = 29; 59 %). Eleven participants did not enroll in a RCT; among these, ten were female (see Table 1). Interview data from three participants
were eliminated from further analysis because they were
offered non-RCT studies.
Procedure
The protocol approved by the university Institutional Review Board entailed clinic staff identifying patients who
had been offered an RCT in the past 2 years and lived in
(or were treated) in an Appalachian county. Researchers
mailed patients a recruitment letter signed by their treating physician. For three clinics, a researcher conducted
follow-up phone calls to provide additional study information and schedule interviews for those who agreed to
participate. Semi-structured interviews were conducted
by a trained research team member, were audio-recorded,
and ranged from 30 min to 3 h in length. Interviews were
conducted face-to-face at a location of the participant’s
choice (e.g., home, hospital treatment room). After the interview, participants completed a brief, self-administered
survey and were remunerated US$30.00 for their time. The
survey included five true/false items measuring randomization comprehension [15]. Participants received 1 point
for each item answered correctly (range 0–5). Responses
were summed to create a Randomization Comprehension
Index (RCI; Table 2).
Data Analysis
The interview audio files were uploaded to a passwordprotected computer, transcribed verbatim, and imported
into NVivo 10. Transcripts were read multiple times by the
principle investigator (J. L. K.) and three additional members of the data analysis team to familiarize themselves
with the content. Four authors conducted data analysis
through an iterative combination of independent and
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Table 1. Participant characteristics (n = 49)
Characteristic
Sex
Female
Male
Race
White
Asian/Pacific islander
Unreported
Participated in a RCT*
Yes
No
Ineligible (offered a non-RCT study)
Cancer type*
Breast
Multiple myeloma
Prostate
Colon
Lung
Other
Annual income below US$49,000
Yes
No
Health insurance
None
Medicaid/Medicare
Insured through employer
Other
Education
8th grade through some high school
High school diploma or equivalent
Vocational training/associates
College graduate or more

3

Table 2. Randomization Comprehension Index (RCI) items (n = 46)
Number (%)
29 (59)
20 (41)
47 (96)
1 (2)
1 (2)
35 (71)
11 (22)
3 (6)
19 (39)
9 (18)
7 (14)
6 (12)
5 (10)
3 (6)
23 (50)
23 (50)
3 (6)
19 (39)
24 (49)
3 (6)
4 (8)
19 (39)
17 (35)
9 (18)

*Values do not equal 100 % due to rounding

collaborative coding over a period of 16 weeks [16]. First,
thought units pertaining to uncertainty were identified and
open-coded as a team. Second, transcripts were opencoded independently followed by weekly meetings to
compare the textual composition and conceptual labeling of thought units in each transcript, discuss discrepancies, and negotiate agreement [17, 18]. Third, axial coding
was used to compare codes within and across transcripts,
resulting in the creation of categories. A codebook was
created and continually refined throughout the process
that included conceptual labels, definitions, examples, and
negative cases for each category. The resulting categories
are discussed in detail in the following section.
There were a number of measures taken throughout the
data collection and analysis process to ensure the trustworthiness of the findings [19]. Credibility was enhanced
through triangulation, in that the textual composition and
labeling of codes were agreed upon by at least two (and

Question

Number (% correct)

RCI 1: In a clinical trial, randomization
means that a patient is just as likely to
get one treatment as another

34 (74 %)

RCI 3: Doctors who place their patients in
clinical trials often choose the treatment
that their patients should receive.

29 (63 %)

RCI 5: The goal of a clinical trial is to match
people to the best treatment for them

22 (48 %)

RCI 2: Randomization means that patients
in a clinical trial are allowed to choose a
treatment out of a list of options.

RCI 4: In a clinical trial, one way to decide a
patient’s treatment would be to toss a coin.

33 (72 %)

8 (17 %)

up to four) investigators. Dependability and confirmability
were ensured through extensive theoretical and process
memoing. Our audit trail includes memos for each interview (created during data collection) and each transcript
(created during data analysis). Furthermore, the team kept
a memo describing key decisions and developments in the
data analysis process.

Results and Interpretations
Randomization Comprehension and RCT Participation
Participants were divided into high and low randomization comprehension groups based on their RCI score (see
Table 2). High comprehension patients had an overall RCI
score of 4 or 5 (n = 18; 39 %). Low comprehension patients
had an overall RCI score of 3 or lower (n = 28; 61 %). A
goodness-of-fit (chi-square) analysis found no statistically
significant differences between the RCI scores of patients
who participated in a RCT as compared to those who declined (see Table 3).
Randomization Comprehension and Uncertainty
Overall, comprehension of randomization (as measured
by the RCI) was conceptually distinct from uncertainty,
Table 3. Randomization Comprehension Index scores of RCT
participants versus nonparticipants
RCI Score
0–3 items correct
4–5 items correct
χ2 (1, n = 46) = .05, p = .83

Clinical trial

Total

Yes

No

21
14

7
4

28
18

4

with patients at all levels of comprehension experiencing
randomization-related uncertainty. However, patients described two different types of uncertainty associated with
the randomization process: (1) cognitive dimensions and
(2) affective dimensions.
Cognitive Dimensions of Uncertainty about
Randomization
Cognitive dimensions of uncertainty were thought units
pertaining to perceived ambiguity about procedural aspects of randomization, such as assignment to treatment
groups and probability of receiving effective treatment. Patients reported that their oncologists used a variety of descriptions for explaining randomization to treatment arms,
including flipping a coin, lottery process, and a computer
(described below). Many patients struggled with these explanations because they could not visualize the procedures
being used to assign patients to treatment. For example,
Jeanine, a patient with low comprehension of randomization (RCI = 2), agreed to participate in an RCT. When randomization was explained to her, she laughed and said,
“You’re gonna put my name in a hat and draw us out and
see which one I’m gonna get?” As illustrated by this quote,
patients recognized these explanations of randomization as
metaphorical in that researchers would not be literally flipping coins or drawing slips of paper out of a hat in order to
assign them to their treatment. However, using metaphors
to describe the process did little to reduce patient uncertainty about who would be determining which treatment
they would receive or how that decision would be made.
Some healthcare providers tried to convey the idea that
a patient’s treatment is chosen randomly by a computer.
However, this explanation was also associated with uncertainty. Patients are accustomed to computers being used to
deliver highly individualized medical care, such as recording their medical history through electronic medical records.
Given that computers are typically used to provide individualized patient care, such as identify whether a patient is at
risk for potential drug interactions, patients had difficulty
understanding why the computer would not use the information in their medical record to match them to the best
possible treatment. To illustrate, Alice agreed to participate
in a RCT. Despite having a high level of randomization comprehension (RCI = 5), she expressed confusion about the
role of probability in determining how her treatment was
chosen. She stated, “He (health care provider) told me the
computer would pick what group I was in, whether I would
be in the control group or the test group (…) it’s just random (…) It was pretty confusing.” Although Alice understood randomization at a conceptual level, she did not understand why the computer would make a determination
“at random” when information was available in her electronic medical records that could be used to match her to
the most appropriate treatment. The relationship between
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computers and the randomization process in an RCT demonstrates the tension between patient expectations of individualized care and the seemingly impersonal nature of
how randomization was conducted.
The second procedural concern was the probability of
receiving effective treatment in the RCT. Many patients
misinterpreted the role of probability as the chance of receiving treatment for their cancer, not the chance of receiving one of two (or more) possible treatments. Samantha
had high comprehension of randomization (RCI = 4) but
declined participation in a RCT because, “There’s a possibility you don’t get the proper treatment. And I think later
on, when I talked to different people, that’s really not the
case. I think you get—I don’t know. I’m still a bit confused
on that.” She went on to explain that she was more comfortable with a more personalized treatment plan: “I just
wanted the best—you know, I wanted to make the best
decision. I just felt like the best decision was the known
plan or the plan laid out by the doctor not an experimental (study).” Similarly, Kristy (RCI = 3) participated in an RCT,
but was concerned that randomization meant that she
might not receive treatment for her cancer:
When I signed up for (the RCT), I just worried about
whether I was getting the drug or not getting the drug.
You know, I’d say, ‘Well, what arm am I gonna be in?’ And I
think I’d have probably been disappointed if I would have
gotten the placebo. That thinking all along that maybe I’m
taking a drug, and it’s gonna be helping me. And then to
find out that, ‘Oh, I didn’t really get it.’

Affective Dimensions of Uncertainty about
Randomization
Affective dimensions of uncertainty refer to the emotional
valence of patient descriptions of randomization. Given that
randomization entails uncertainty, we examined the extent
to which patients used emotionally valenced terms to describe how patients would be allocated to treatment condition. As would be expected, the affective tone of randomization narratives ranged from neutral to negative. Neutral
narratives were those that utilized impersonal or scientific
explanations of equal chance in allocation to treatment arm.
For example, Gloria, who agreed to participate in an RCT, had
a relative strong understanding of randomization (RCI = 4).
She was matter-of-fact in describing how randomization was
explained to her by a health care provider (HCP) during her
treatment decision-making process:
Some people will get the additional drug, and some won’t.
And if you decide to sign up for the study, we (HCP) won’t
know if you’re one of them that will get it or not until we
get all the information entered into the computer. Then,
it will tell us (HCPs).

Narratives reflecting a negative affective valence contained implicit disapproval (e.g., sarcasm) or explicit use of

comprehension of randomization and uncertainty in cancer patients

negative terminology to describe the randomization process. Samantha, like Gloria, had a strong understanding
of randomization (RCI = 4). Unlike Gloria, Samantha chose
not to enroll in the RCT. In the following excerpt, Samantha verbalizes a negative affective response to the role
of probability in determining her treatment. Specifically,
she uses sarcasm (“my luck”) and dehumanizing language
(“you’re a number”) to refer to the potential of being assigned to the treatment arm utilizing a placebo. Finally, she
contrasts the “placebo” treatment to arms that are “overaggressive” and “middle of the road” indicating she perceived the RCT as offering an ineffective treatment arm
despite her acknowledgement that patients receive treatments in addition to the placebo:
One group would get this, this, and this, which is kind of
like over aggressive and one group would get this, this,
and this, which is kind of like your middle-of-the-road, and
one group would get some placebos and this and this. So
I’m thinking, ‘Well, my luck, I’ll be in the group three.’ And
you don’t know and they don’t know (…) You’re a number and you get in a bin and we can’t say we want you to
get this treatment or we want you to get that treatment.

In other cases, patients produced negatively valenced
narratives as indicated by the use of specific terminology
with a negative connotation. Cathy had a strong understanding of randomization (RCI = 4) but chose not to enroll in an RCT. She articulated her concern in the following
way, “Had there been one thing that might have helped, I
would have probably (enrolled in the RCT). But, they didn’t
know that. You know, that’s why it’s a trial.” In this example,
Cathy equates a clinical trial with the colloquialism trial
and error, which has overtly negative connotations in the
context of cancer treatment.
Guinea pig was another term used to express negative
feelings toward randomization by patients at various levels of randomization comprehension. For example, Tracy
(RCI = 4) and Taylor (RCI = 1) both refused RCT participation. Tracy stated that the most influential factor in her decision not to participate was “the scariness of it really not
being approved by the FDA. You know, using something
kind of like a guinea pig type thing.” Similarly, Taylor said,
“You get the cutting edge treatment or drugs or whatever
they had but then on the other hand, were you going to
be used as a guinea pig for new stuff?” Tracy and Taylor
illustrate that cognitive comprehension of randomization
may be unrelated to their affective response to the process.

Discussion
RCTs are an important pathway for investigating successful cancer treatments. While RCTs help reduce scientific
uncertainty about treatment efficacy, the role of randomization in determining treatment increases the medical

5

uncertainty of patients. The purpose of the current study
was to explore the relationship between patient comprehension of randomization, treatment uncertainty, and willingness to participate in cancer RCTs. We found no evidence of a statistically significant association between
randomization comprehension and participation in cancer RCTs. We posit that randomization comprehension is
conceptually distinct from uncertainty, as patients with all
levels of comprehension experienced uncertainty. Finally,
we showed that randomization uncertainty has both cognitive and affective dimensions.
Cognitive dimensions of uncertainty involved statements expressing concern about how randomization
would be accomplished and the role of probability in determining treatment. These statements revealed that being assigned to treatment by chance was conceptually at
odds with mental models of medicine grounded in an expectation of personalized care as well as the belief that
medicine is a science and operates according to a system
of rules and proven practices. Thus, the notion that an oncologist cannot choose the treatment that best matches
the patient’s cancer in a RCT was unsettling to patients.
Affective dimensions of uncertainty were statements revealing emotional reactions to the role of randomization
in determining treatment. In some cases, patients revealed
their emotional responses through the use of irony or sarcasm in their descriptions of randomization while others
used overtly negative words, such as “trial and error” and
“guinea pig.” Addressing patient concerns and emotions
about the safety of randomization are vital in the RCT accrual process, a finding that complements and extends results from previous studies [8, 9].
An unexpected finding was that patients expressing
both cognitive and affective dimensions of uncertainty
had participated in a RCT. The fact that patients consented
to participate in research despite significant uncertainty
about treatment efficacy indicates a dire need to develop
translational communication strategies to promote patient
comprehension of scientific design in the medical context.
A major source of misinformation was the belief that one
treatment arm was superior to the others or that one arm
was vastly inferior to the others. Given that RCTs are conducted only in cases of clinical equipoise, it is noteworthy
that patients did not view the arms as equivalent. Instead,
patients over- or underestimated the known efficacy and
safety of the experimental arm.
The current study benefits from a number of strengths.
Noteworthy methodological strengths include recruiting
an underrepresented population of Appalachian cancer
patients who had been offered an opportunity to participate in a cancer RCT, a substantial sample, and a rigorous analytical approach. The specific focus on Appalachian
cancer patients illuminates the potentially unique concerns of rural cancer patient populations and contributes

6
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an understanding of RCT recruitment among rural, Appalachian cancer patients, a population that experiences
significant cancer incidence and mortality disparities [20].
There are study limitations that should be noted. First, the
generalizability of our findings beyond rural, Appalachian
populations is limited. Furthermore, the selection criteria
included all types of cancers and treatments; therefore,
the results could not be generalized to studies focusing
on a specific diagnosis(es) or particular RCTs. Future research should investigate how cancer type, stage, and type
of treatment offered is associated with the likelihood of
participating in an RCT.
The results of the current research have important practical implications. Efforts to improve informed consent to
participate in RCTs should focus on having patients teach
back their understanding of randomization. This practice
affords providers the opportunity to assess a patient’s cognitive and affective understanding of randomization as well
as opportunities to correct misperceptions. Also, education
about RCTs should reflect patient expectations of individualized care by explaining how all treatments being compared are appropriate to the specifics of a patient’s disease.
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